And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. We have a modest agenda that includes catching up with family and friends, and hopefully, our reading, as well. A few naps are also envisioned. And what about you? This is a lovely time of year to explore the great outdoors. Those of you with a sense of adventure could mosey among garage sales seeking hard-to-find treasures. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Pfizer is offering its Ibrance breast cancer drug free to the UK National Health Service while cost regulators decide if it should be routinely funded, PharmaTimes says us. The drug was approved last November as a first-line treatment, but in February, the National Institute for Health and Care Excellence rejected the drug, which costs nearly $100,000, after concluding trial data could not quantify progression-free survival.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy